Level B· Emerging clinical evidence with positive signalsClinical TrialPubMed

Our Fat Future: Translating Adipose Stem Cell Therapy.

Nordberg RC., Loboa EG.

Clinical Trial, published in Stem Cells Transl Med (2015) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cells Transl Med (2015)
Country
England
Reported sample size
—
Source database
PubMed
PMID
26185256
PMCID
PMC4542878
DOI
10.5966/sctm.2015-0071
Citations
39

Abstract (original English)

Unlabelled Human adipose stem cells (hASCs) have the potential to treat patients with a variety of clinical conditions. Recent advancements in translational research, regulatory policy, and industry have positioned hASCs on the threshold of clinical translation. We discuss the progress and challenges of bringing adipose stem cell therapy into mainstream clinical use. Significance This article details the advances made in recent years that have helped move human adipose stem cell therapy toward mainstream clinical use from a translational research, regulatory policy, and industrial standpoint. Four recurrent themes in translational technology as they pertain to human adipose stem cells are discussed: automated closed-system operations, biosensors and real-time monitoring, biomimetics, and rapid manufacturing. In light of recent FDA guidance documents, regulatory concerns about adipose stem cell therapy are discussed. Finally, an update is provided on the current state of clinical trials and the emerging industry that uses human adipose stem cells. This article is expected to stimulate future studies in translational adipose stem cell research.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
AdipocytesAdipose TissueAutomation, LaboratoryBiomimetic MaterialsBiosensing TechniquesCell DifferentiationCell- and Tissue-Based TherapyClinical Trials as TopicHumansStem Cell Transplantation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.